Oneview Healthcare Reports Strong H2 2025 Results

Company highlights accelerating deployment activity, continued U.S. focus, and growing role for AI in product development and operations.

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Oneview Healthcare (ASX:ONE) reported full-year 2025 results, with management highlighting a 21% increase in revenue, a 3 percentage point decline in gross margin, and an 8% reduction in operating EBITDA loss. The company emphasized a reduction in operating expenses in the second half following a restructuring and additional efficiencies. Oneview ended 2025 with 14,800 live endpoints and is targeting an endpoint base of just under 18,000 by the end of 2026, supported by recent product additions and a 'land and expand' strategy. The company also discussed its shift from focusing on beds to focusing on endpoints, as well as initiatives around AI-powered product development and the launch of a new staff-facing product, OVI Console.

Why it matters

Oneview Healthcare's strong H2 2025 results and forward-looking initiatives demonstrate the company's ability to navigate challenges and capitalize on growth opportunities in the healthcare technology sector. The company's focus on expanding its product portfolio, improving operational efficiency, and leveraging AI for product development highlights its commitment to innovation and meeting the evolving needs of its healthcare clients.

The details

Oneview Healthcare reported a 21% increase in revenue in 2025 versus 2024, driven by an increase in non-recurring revenue and 7% growth in annual recurring revenue. Gross margin declined by 3 percentage points to 64%, which the company attributed to revenue mix. Operating EBITDA loss improved by 8% to EUR 8.1 million, which the company said was due to higher revenue while cash operating expenses remained consistent with 2024. Management emphasized a reduction in operating expenses in the second half following a restructuring and additional efficiencies, with H2 2025 cash OpEx 9% lower than H1 2025 and 13% lower than H2 2024.

  • Oneview Healthcare reported full-year 2025 results (year ended December 2025).
  • The company executed a restructuring in May 2025.
  • Oneview ended 2025 with 14,800 live endpoints and is targeting an endpoint base of just under 18,000 by the end of 2026.

The players

Oneview Healthcare

An ASX-listed company that develops and sells software and related consultancy services for the healthcare sector in Ireland, the United States, Australia, Asia, and the Middle East.

Darragh Lyons

The Chief Financial Officer of Oneview Healthcare.

James Fitter

The Chief Executive Officer of Oneview Healthcare.

Niall O'Neill

The Chief Product Officer of Oneview Healthcare.

Michael Dowling

The CEO for the past 23 years of a large New York health system, who was recently added to Oneview Healthcare's board.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.